Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 19, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on administrative adjustments to notional share allocations within a retirement plan.
Material Changes
The filing details restatements and new notifications regarding the notional allocation of GSK Ordinary share ADRs following a revaluation of the cash element of the investment:
- New Allocation: Dr. R.G. Greig received an increase of 2 ADRs on December 14, 2007, at a price of $53.00 per ADR.
- Restated Allocations: Previous increases announced on November 2, 2007, were restated for several individuals (e.g., Mr. W. Louv increased from 6 to 7 ADRs; Dr. R.G. Greig decreased from 89 to 88 ADRs).
- Correction: A prior announcement on November 28, 2007, regarding Dr. R.G. Greig was corrected from 3,287 ADRs to 3,279 ADRs at a price of $50.19 per ADR due to a technical calculation error.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The unusual items noted are strictly technical recalculations of notional ADR holdings advised by a third party.
Investor Verification Points
- Verify the corrected notional ADR counts for Dr. R.G. Greig and other named directors.
- Confirm the specific pricing ($53.00, $51.25, $50.19) used for the respective transaction dates.
- Note that this filing does not reflect operational or financial performance changes for the company.